Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 9.2% – What’s Next?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares traded up 9.2% during trading on Monday . The stock traded as high as $2.99 and last traded at $2.97. 4,240,547 shares were traded during mid-day trading, a decline of 10% from the average session volume of 4,688,567 shares. The stock had previously closed at $2.72.

Key Stories Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue surged ~144% year‑over‑year to $168.4M and topped estimates, showing strong commercial traction. Read More.
• Positive Sentiment: Full‑year 2025 results showed revenue growth (FY25 total revenue +21% Y/Y; U.S. net product revenue +38% Y/Y), supporting the company’s commercial progress. Read More.
• Positive Sentiment: Management announced an acquisition alongside the results, which earlier triggered intraday upside in some coverage and was cited as a potential near‑term catalyst. Read More.
• Positive Sentiment: HC Wainwright maintains a Buy rating and provided an EPS forecast for the quarter, signaling at least one sell‑side firm remains constructive. Read More.
• Neutral Sentiment: Earnings call transcript, slide deck and presentation materials are available for detail on product uptake, margin trends and guidance—useful for investors deciding whether the revenue beat offsets the EPS miss. Read More.
• Neutral Sentiment: Reported short‑interest data in the feeds is anomalous (shows 0 shares / 0 days‑to‑cover); no clear short squeeze or covering signal from those entries. (Data appears unreliable.)
• Negative Sentiment: EPS of $0.22 missed consensus by ~$0.01 ($0.23), and that small miss weighed on sentiment despite the revenue beat — cited in multiple reports as the proximate cause of the stock pullback. Read More.
• Negative Sentiment: Market headlines emphasized the “mixed” print and some retail‑driven selling, amplifying near‑term downside pressure. Read More.

Wall Street Analyst Weigh In

ESPR has been the topic of several research analyst reports. Needham & Company LLC raised their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday. Piper Sandler began coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

Esperion Therapeutics Price Performance

The firm’s 50-day moving average price is $3.35 and its 200-day moving average price is $3.14. The company has a market cap of $618.70 million, a price-to-earnings ratio of -5.18, a price-to-earnings-growth ratio of 0.62 and a beta of 1.11.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million. On average, sell-side analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Insider Buying and Selling at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the completion of the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 15,543 shares of company stock valued at $55,709 in the last ninety days. 1.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Esperion Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its stake in Esperion Therapeutics by 17.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 36,744 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 5,492 shares during the last quarter. Invesco Ltd. increased its position in shares of Esperion Therapeutics by 23.5% in the 4th quarter. Invesco Ltd. now owns 765,118 shares of the biopharmaceutical company’s stock worth $2,831,000 after purchasing an additional 145,351 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Esperion Therapeutics by 23.5% in the 4th quarter. Mackenzie Financial Corp now owns 336,992 shares of the biopharmaceutical company’s stock worth $1,241,000 after purchasing an additional 64,034 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $599,000. Finally, nVerses Capital LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth about $250,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.